Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.36 |
| ▸ | CES1 | P23141 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphine SCHEMBL28854043 | 0.97 | CES2 (0.35) | CES2CES1CA12CA1CA9 | |
| SCHEMBL14733078 | 0.84 | CES2 (0.32) | CES2CES1CA12CA1CA9 | |
| SCHEMBL29920955 | 0.80 | MAPT (0.37) | CES2CES1ALDH1A1MAPTKMT2A | |
| SCHEMBL4745988 | 0.80 | CA9 (0.44) | CES2CES1CA12CA1CA9 | |
| SCHEMBL29812175 | 0.80 | CA9 (0.44) | CES2CES1CA12CA1CA9 | |
| SCHEMBL18775342 | 0.80 | CES2 (0.30) | CES2CES1 | |
| SCHEMBL12074048 | 0.80 | RAPGEF4 (0.40) | CES2CES1RAPGEF4 | |
| SCHEMBL4607963 | 0.80 | MAPT (0.37) | CES2CES1ALDH1A1MAPTKMT2A | |
| SCHEMBL18101290 | 0.79 | TTR (0.33) | — | |
| SCHEMBL21279638 | 0.76 | CES2 (0.32) | CES2CES1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362860-B1 | Method for producing tetrakis (fluoraryl)borate magnesium compound | NIPPON CATALYTIC CHEM IND (JP) | 2010-09-15 | — | — | EP | claimed |
| US-7205441-B2 | Method for producing tetrakis (fluoroaryl) borate-magnesium compound | NIPPON SHOKUBAI CO., LTD. (JP) | 2007-04-17 | — | — | US | claimed |
| US-20030216598-A1 | Method for producing tetrakis ( fluoroaryl) borate-magnesium compound | NIPPON SHOKUBAI CO., LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| EP-1362860-A1 | Method for producing tetrakis (fluoroaryl) borate magnesium compound | Nippon Shokubai Co., Ltd. (JP) | 2003-11-19 | — | — | EP | claimed |
| US-20250074938-A1 | CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-03-06 | — | — | US | disclosed |
| CN-119462647-A | Aromatic condensed ring compound, pharmaceutical composition containing aromatic condensed ring compound and application of aromatic condensed ring compound | 杭州禹泓医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-118693282-B | Secondary battery and preparation method and application thereof | 蜂巢能源科技股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-118693282-A | Secondary battery and preparation method and application thereof | 蜂巢能源科技股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-118451090-A | Amide antiviral compound | 海南先声药业有限公司 | 2024-08-06 | — | — | CN | disclosed |
| EP-3681928-B1 | PROCESS OF MANUFACTURING POLYOLS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20230371357-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230309379-A1 | LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-09-28 | — | — | US | disclosed |
| CN-1356331-A | Process for preparing metallic fluoroaryl ampound | NIPPON CATALYTIC CHEM IND (JP) | 2002-07-03 | — | — | CN | disclosed |
| EP-1211255-A2 | Method for producing fluoroaryl metal compound | Nippon Shokubai Co., Ltd. (JP) | 2002-06-05 | — | — | EP | disclosed |
| US-20020065426-A1 | Method for producing fluoroaryl metal compound | NIPPON SHOKUBAI CO., LTD (JP) | 2002-05-30 | — | — | US | disclosed |
| US-6235222-B1 | REACTING, IN SOLVENT CONTAINING CHAIN ETHER SOLVENT, HYDROCARBON MAGNESIUM HALIDE WITH FLUOROARYL HALIDE | NIPPON SHOKUBAI CO., LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0995753-A2 | Method for manufacturing fluoroaryl magnesium halide | Nippon Shokubai Co., Ltd. (JP) | 2000-04-26 | — | — | EP | disclosed |
| EP-0109606-B1 | PROCESS FOR THE FORMYLATION OF ARYL HALIDES | BAYER AG (DE) | 1986-01-22 | — | — | EP | disclosed |
| US-4536344-A | USING A PHOSPINE OR PHOSPHITE | BAYER AKTIENGESELLSCHAFT (DE) | 1985-08-20 | — | — | US | disclosed |
| EP-0109606-A1 | Process for the formylation of aryl halides | BAYER AG (DE) | 1984-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074938-A1 | CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES | ACE, TMPRSS2, ACE2 | CES2 293/4885CES1 127/4885CA12 606/4885 |
| US-20030216598-A1 | Method for producing tetrakis ( fluoroaryl) borate-magnesium compound | KRAS, MGAM, CA3 | CES2 3957/4885CES1 4605/4885CA12 747/4885 |
| US-20230371357-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | L1CAM, CHRM1, FOXM1 | CES2 2295/4885CES1 1770/4885CA12 2600/4885 |
| US-20020065426-A1 | Method for producing fluoroaryl metal compound | DDT, TERT, HACL2 | CES2 3276/4885CES1 3890/4885CA12 3603/4885 |
| US-20230309379-A1 | LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND | CRY1, LEF1, LAGE3 | CES2 2364/4885CES1 1181/4885CA12 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.